Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

BC051019 Activators

Activators of the BC051019 protein, known as BC051019 activators, are a chemical class designed to upregulate the activity of this specific protein. The journey of identifying these molecules typically begins with high-throughput screening (HTS), which is an automated process that can rapidly test a large number of compounds for their ability to affect the activity of BC051019. During this phase, a diverse chemical library is screened against the target protein, using assays that are quantitative and produce measurable signals like fluorescence or luminescence when BC051019 activity is altered. Compounds that show an increase in the activity of the BC051019 protein are considered hits and are selected for further validation. Secondary assays, which are more specific and stringent than the primary HTS, are then conducted to ensure that these hits are indeed true activators of BC051019. These secondary tests help to filter out any non-specific activators or compounds that produce a signal through an indirect mechanism unrelated to BC051019 activation.

Following the identification and validation of potential BC051019 activators, a detailed characterization of their interaction with the BC051019 protein is undertaken. Techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy can be employed to elucidate the structural details of the activator-BC051019 complex. These structural insights are crucial for understanding how these activators enhance the protein's activity by revealing the binding sites and conformational changes induced upon interaction. Additionally, biophysical methods like surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are used to obtain quantitative information about the binding kinetics and affinity of the activators to BC051019. This data allows for the determination of how readily the activators bind to the protein and the strength of the interaction. Furthermore, structure-activity relationship (SAR) studies play a critical role in the optimization process.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Ionomycin

56092-82-1sc-3592
sc-3592A
1 mg
5 mg
$78.00
$270.00
80
(4)

Ionomycin is a calcium ionophore that raises intracellular calcium levels, potentially activating calcium-dependent proteins, which could include "BC051019" if it is calcium-sensitive.

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA is a PKC activator which could enhance the activity of "BC051019" if it is modulated by PKC-mediated phosphorylation.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

EGCG is a kinase inhibitor that could potentially enhance the activity of "BC051019" by inhibiting competing kinase pathways, thus indirectly influencing its activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a PI3K inhibitor that could enhance the activity of "BC051019" by altering signaling pathways downstream of PI3K if "BC051019" is involved in these pathways.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$64.00
$246.00
136
(2)

U0126 is a MEK inhibitor that could shift the balance of signaling towards pathways involving "BC051019" if it is part of the MAPK/ERK pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 inhibits p38 MAPK, potentially enhancing pathways that "BC051019" is part of if it is negatively regulated by p38 MAPK signaling.

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 acts as a calcium ionophore, enhancing calcium-dependent pathways, and could increase the activity of "BC051019" if it is calcium-regulated.

Zaprinast (M&B 22948)

37762-06-4sc-201206
sc-201206A
25 mg
100 mg
$105.00
$250.00
8
(2)

Zaprinast inhibits PDE5 like Sildenafil and could similarly enhance "BC051019" activity if it is involved in cGMP-mediated signaling.

NSC 23766

733767-34-5sc-204823
sc-204823A
10 mg
50 mg
$151.00
$609.00
75
(4)

NSC 23766 inhibits Rac1-GEF interaction, which could enhance "BC051019" activity if it is involved in cell signaling pathways regulated by Rac1.

GSK-3 Inhibitor IX

667463-62-9sc-202634
sc-202634A
sc-202634B
1 mg
10 mg
50 mg
$58.00
$188.00
$884.00
10
(1)

This compound inhibits GSK3β, which could lead to the activation of "BC051019" if it is regulated by GSK3β-dependent phosphorylation.